JPX · 2689.T
OLBA HEALTHCARE HOLDINGS, Inc.
¥1,920+¥9 (+0.47%)
OLBA HEALTHCARE HOLDINGS, Inc.’s quoted price sits in the lower half of its reported 52-week range, 14.21% below the high.
Loading market information…
JPX · 4584.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Kidswell Bio Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kidswell Bio Corporation’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kidswell Bio Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥1,920+¥9 (+0.47%)
OLBA HEALTHCARE HOLDINGS, Inc.’s quoted price sits in the lower half of its reported 52-week range, 14.21% below the high.
¥638-¥9 (-1.39%)
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
¥578-¥9 (-1.53%)
Japan Medical Dynamic Marketing, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.49% below the high.
¥411-¥11 (-2.61%)
Stella Pharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 58.69% below the high.
$1.40-$0.07 (-4.76%)
MediciNova, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.1% below the high.
¥188-¥7 (-3.59%)
CellSeed Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.66% below the high.
¥89-¥3 (-3.26%)
Chiome Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
¥79-¥1 (-1.25%)
Nano Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.49% below the high.
